Ocular Therapeutix Management

Management Kriterienprüfungen 1/4

Ocular Therapeutix CEO ist Pravin Dugel , ernannt in Apr 2024, hat eine Amtszeit von weniger als ein Jahr. besitzt direkt 0.064% der Aktien des Unternehmens, im Wert von $1.03M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 0.8 Jahre bzw. 5.4 Jahre.

Wichtige Informationen

Pravin Dugel

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	0.06%
Durchschnittliche Amtszeit des Managements	less than a year
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.4yrs

Jüngste Management Updates

Recent updates

Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

Oct 16

Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors

Oct 11

Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Aug 10

Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors

Jul 23

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 41% But Its P/S Still Looks Reasonable

Jul 15

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Jun 05

Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results

Jun 01

Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking

Jan 09

Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?

Oct 15

Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

Jun 30

Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Mar 08

Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?

Feb 11

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be

Nov 16

Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt

Sep 09

Ocular Therapeutix: Trading Ahead Of An Underappreciated Catalyst Event

Aug 15

Geschäftsführer

Pravin Dugel (60 yo)

less than a year

Amtszeit

Dr. Pravin U. Dugel, M. D. has been Executive Chairman of Ocular Therapeutix, Inc. since February 2024 and also serves as its Chief Executive Officer and President since April 15, 2024. He served as Presid...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Donald Notman	CFO, COO & Principal Accounting Officer	7.2yrs	US$1.34m	0.052% $ 829.5k
Jeffrey Heier	Chief Scientific Officer	less than a year	US$329.90k	0.045% $ 720.4k
Pravin Dugel	Executive Chairman	less than a year	keine Daten	0.064% $ 1.0m
Peter Jarrett	Chief Technology Officer	no data	keine Daten	keine Daten
William Slattery	Vice President of Investor Relations	no data	keine Daten	keine Daten
Todd Anderman	Chief Legal Officer & Corporate Secretary	no data	keine Daten	keine Daten
William Ransone	Vice President of Global Sales & Marketing	no data	keine Daten	keine Daten
Tracy Smith	Vice President of Human Resources	4.2yrs	keine Daten	keine Daten
Steve Meyers	Chief Commercial Officer	1.8yrs	keine Daten	keine Daten
Peter Kaiser	Chief Development Officer	less than a year	keine Daten	0.0091% $ 145.1k
Sanjay Nayak	Chief Strategy Officer	less than a year	keine Daten	0.11% $ 1.8m
Nadia Waheed	Chief Medical Officer	no data	keine Daten	keine Daten

0.8yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrenes Management: OCULDas Führungsteam des Unternehmens gilt nicht als erfahren ( 0.8 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Pravin Dugel	Executive Chairman	less than a year	keine Daten	0.064% $ 1.0m
Charles Warden	Lead Independent Director	16.8yrs	US$303.61k	0.031% $ 497.7k
Merilee Raines	Independent Director	3.2yrs	US$263.61k	0.013% $ 215.1k
Richard Lindstrom	Independent Director	12yrs	US$261.11k	0.097% $ 1.5m
Adrienne Graves	Independent Director	1.3yrs	US$397.89k	0.0051% $ 82.1k
Leslie Williams	Independent Director	5.7yrs	US$261.11k	0.016% $ 261.2k
Seung Hong	Independent Director	5.4yrs	US$248.61k	0.013% $ 215.1k

5.4yrs

Durchschnittliche Betriebszugehörigkeit

66yo

Durchschnittliches Alter

Erfahrener Vorstand: OCULDie Vorstandsmitglieder gelten als erfahren (5.4 Jahre durchschnittliche Amtszeit).

Ocular Therapeutix Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Executive Chairman notifies of intention to sell stock

Ocular Therapeutix, Inc., Annual General Meeting, Jun 12, 2024

Ocular Therapeutix, Inc. Announces CEO Changes

Ocular Therapeutix, Inc. Announces Executive Changes

Ocular Therapeutix, Inc. Announces Management Changes

Ocular Therapeutix, Inc. Appoints Steve Meyers as Chief Commercial Officer

Recent updates

Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

Ocular Therapeutix, Inc. Announces Accelerated Timelines for Sol-1 Registrational Trial of AXPAXLI in Wet AMD

Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors

Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Ocular Therapeutix, Inc. Announces Fda Feedback That Sol-R Trial Is Appropriate as A Registrational Study in Wet Amd

Ocular Therapeutix, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Ocular Therapeutix, Inc. Announces First Patients Enrolled in Phase 3 Sol-R Wet AMD Study

Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 41% But Its P/S Still Looks Reasonable

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results

Executive Chairman notifies of intention to sell stock

Consensus EPS estimates fall by 23%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Ocular Therapeutix, Inc. to Report Q1, 2024 Results on May 07, 2024

Ocular Therapeutix, Inc., Annual General Meeting, Jun 12, 2024

Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Ocular Therapeutix, Inc. Announces CEO Changes

Ocular Therapeutix, Inc. Announces Executive Changes

Consensus EPS estimates fall by 29%

Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Ocular Therapeutics' Impressive Surge: A Strategic Insight

Consensus EPS estimates upgraded to US$0.67 loss, revenue downgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocular Therapeutix, Inc. to Report Q4, 2023 Results on Mar 11, 2024

Ocular Therapeutix, Inc. Announces Management Changes

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA

Ocular Therapeutix, Inc. Appoints Steve Meyers as Chief Commercial Officer

Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement

President notifies of intention to sell stock

President recently sold US$91k worth of stock

President notifies of intention to sell stock

Ocular Therapeutix Announces FDA Agreement to Amend Special Protocol Assessment (Spa) for Pivotal Clinical Trial of Axpaxli in Wet AMD

Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD

Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking

Price target decreased by 9.7% to US$11.86

Ocular Therapeutix, Inc. has completed a Follow-on Equity Offering in the amount of $100.1 million.

Ocular Therapeutix, Inc. has completed a Follow-on Equity Offering in the amount of $100.1 million.

New minor risk - Profitability

Third quarter 2023 earnings: EPS exceeds analyst expectations

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Full Year 2023

Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

AffaMed Therapeutics Announces Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery

New minor risk - Share price stability

Ocular Therapeutix, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?

Ocular Therapeutix, Inc. Announces Initiation of Its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

Ocular Therapeutix, Inc. Submits Request for Special Protocol Assessment to the U.S. Food and Drug Administration

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ocular Therapeutix, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Ocular Therapeutix™ Announces Appointment of Adrienne L. Graves as New Board Member

Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

New minor risk - Share price stability

Ocular Therapeutix, Inc. Completes Enrollment of the Helios Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy

Ocular Therapeutix, Inc. Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target increased by 7.8% to US$12.63

Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ocular Therapeutix™ Announces Interim 10-Month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD

Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?

President notifies of intention to sell stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be

Consensus revenue estimates fall by 13%

Insufficient new directors

Price target decreased to US$13.29

Third quarter 2022 earnings: EPS and revenues miss analyst expectations